Alexander T
A: Many patients report improved energy levels within days of beginning treatment
tuftsin analog Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) Formula / M.W.: CHNO, ~751.86 g/mol CAS: 129954-34-3 Form: Sterile nasal spray solution Net per vial: 10 mL (~100 sprays) Total Content: 35 mg combined active per vial Concentration: Pinealon 2.0 mg/mL + DSIP 0.5 mg/mL + Selank 1.0 mg/mL Purity: 99% by HPLC (per component) Identity: MS-verified (per COA) Storage: Refrigerate 28 C, protect from light Disclaimer This product is intended for laboratory research use only
The main ongoing studies: REDEFINE 1 , Phase 3 obesity without T2D (results 20242025, preliminarily 25.3 %) REDEFINE 2 , Phase 3 obesity + T2D REDEFINE 3 , Phase 3 cardiovascular outcome trial (n~7000) Stand-alone clinical development of Cagrilintide is limited , Novo Nordisk is primarily investing in the CagriSema combination
This combination enables investigation of synergistic angiogenesis mechanisms and multi-pathway cellular migration in laboratory models
Research also suggests potential involvement in regulating cytokines such as IL-6 and pathways such as NF-B and MAPK